icon-    folder.gif   Conference Reports for NATAP  
  11th IAS Conference on HIV Science 18-21 July 2021
Back grey_arrow_rt.gif
Lenacapavir; Islatravir, Doravirine at IAS 2021
  Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV - (03/15/21)
IAS: Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) - (07/20/21)
IAS: Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) - (07/20/21)
IAS: Long-acting Capsid Inhibitor Effective as PrEP Against Vaginal SHIV Transmission in Macaques - (07/22/21)
IAS: Safety and Pharmacokinetics of Oral Islatravir Once Monthly for HIV Pre-exposure Prophylaxis (PrEP): Week 24 Analysis of a Phase 2a Trial - (07/22/21)
Doravirine, Islatravir Safety, Metabolics at IAS 2021
IAS: Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine - (07/19/21)
Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks Islatravir/Doravirine Adverse Events Less Frequent in Second Half of 96-Week Trial - (07/22/21)
The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: Results from the DRIVE-AHEAD clinical trial - (07/19/21)